Benitec Biopharma Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Benitec Biopharma Inc. (BNTC) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$45.34 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-14.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-09-14
- Benitec Biopharma Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2026 was -$45.34M.
- Benitec Biopharma Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$37.18M.
- Benitec Biopharma Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$21.04M.
- Benitec Biopharma Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$18.95M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2026-06-30 | -$45.34M 10-K · filed 2026-09-14 | |
| 2025-06-30 | -$37.18M 10-K · filed 2026-09-14 | |
| 2024-06-30 | -$21.04M 10-K/A · filed 2026-03-20 | |
| 2023-06-30 | -$18.95M 10-K · filed 2024-09-26 | |
| 2022-06-30 | -$17.37M 10-K · filed 2023-09-21 | |
| 2021-06-30 | $7.91M 10-K · filed 2022-09-02 | -$7.91M 10-K · filed 2021-09-20 |
| 2020-06-30 | -$299.00K 10-K · filed 2021-09-20 | |
| 2019-06-30 | $169.00K 10-K · filed 2020-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |